PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB
Rheumatoid arthritis (RA) is one of the most common and severe chronic inflammatory diseases. The paper reviews the recent studies evaluating the efficacy of rituximab (MabThera®), chimeric anti-CD20 monoclonal antibodies in B cells, in patients with RA. It has been shown that Rituximab is an extrem...
| প্রধান লেখক: | |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | Russian |
| প্রকাশিত: |
IMA-PRESS LLC
2009-12-01
|
| মালা: | Современная ревматология |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://mrj.ima-press.net/mrj/article/view/261 |
| _version_ | 1826557026537308160 |
|---|---|
| author | Evgeni Lvovich Nasonov |
| author_facet | Evgeni Lvovich Nasonov |
| author_sort | Evgeni Lvovich Nasonov |
| collection | DOAJ |
| description | Rheumatoid arthritis (RA) is one of the most common and severe chronic inflammatory diseases. The paper reviews the recent studies evaluating the efficacy of rituximab (MabThera®), chimeric anti-CD20 monoclonal antibodies in B cells, in patients with RA. It has been shown that Rituximab is an extremely effective and relatively safe drug for the treatment of RA and may be considered to be a prototype for a new line in the management of autoimmune diseases, the basis for which is B-cell immunity modulation. |
| first_indexed | 2024-04-10T02:08:40Z |
| format | Article |
| id | doaj.art-3bb08fc1e4fb45f08f52c1b71a35117d |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2025-03-14T08:22:03Z |
| publishDate | 2009-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-3bb08fc1e4fb45f08f52c1b71a35117d2025-03-02T13:10:53ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2009-12-0134677510.14412/1996-7012-2009-5761566PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMABEvgeni Lvovich NasonovRheumatoid arthritis (RA) is one of the most common and severe chronic inflammatory diseases. The paper reviews the recent studies evaluating the efficacy of rituximab (MabThera®), chimeric anti-CD20 monoclonal antibodies in B cells, in patients with RA. It has been shown that Rituximab is an extremely effective and relatively safe drug for the treatment of RA and may be considered to be a prototype for a new line in the management of autoimmune diseases, the basis for which is B-cell immunity modulation.https://mrj.ima-press.net/mrj/article/view/261ревматоидный артритбазисные противовоспалительные препаратыингибиторы фактора некроза опухоли аритуксимаб |
| spellingShingle | Evgeni Lvovich Nasonov PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB Современная ревматология ревматоидный артрит базисные противовоспалительные препараты ингибиторы фактора некроза опухоли а ритуксимаб |
| title | PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB |
| title_full | PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB |
| title_fullStr | PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB |
| title_full_unstemmed | PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB |
| title_short | PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB |
| title_sort | pharmacotherapy for rheumatoid arthritis in the 21st century focus on rituximab |
| topic | ревматоидный артрит базисные противовоспалительные препараты ингибиторы фактора некроза опухоли а ритуксимаб |
| url | https://mrj.ima-press.net/mrj/article/view/261 |
| work_keys_str_mv | AT evgenilvovichnasonov pharmacotherapyforrheumatoidarthritisinthe21stcenturyfocusonrituximab |